OS and RFS of CN-AML patients based on ERG/EVI1/PRAME score. CN-AML patients were grouped according to favorable (low ERG, low EVI1, or high PRAME) or adverse (high ERG, high EVI1, or low PRAME) expression profile, according to the selected quartile in the individual analysis. Therefore, the proposed score was drawn up by assigning a value of 0 for each gene expressing a favorable RNA level and a value of 1 for each gene with an adverse expression profile. (A-B) OS and RFS for the 121 CN-AML patients, respectively. (C-D) Survival analyses for 97 CN-AML patients younger than 65. (E-F) Survival analyses for 83 CN-AML patients included within the FLT3/NPM1 intermediate-risk/high-risk subgroups [FLT3wt/NPM1wt (n = 47), FLT3-ITD/NPM1 mutated (n = 20), or FLT3-ITD/NPM1wt (n = 16)]. A 2-year OS of 100%, 64%, 39%, and 27% was observed for scores 0, 1, 2, and 3, respectively (P = .001; E), whereas the 2-year RFS for the same subgroups was 86%, 62%, 43%, and 43% (P = .013; F). Similar results were observed for the other combinations of FLT3 and NPM1, although statistically significant differences were achieved only in the FLT3wt/NPM1wt (OS, P = .016; and RFS, P = .019) because of the sample size in these subgroups. *P < .001 if the analysis is restricted to nonrefractory patients.